Edition:
United States

Xenetic Biosciences Inc (XBIO.OQ)

XBIO.OQ on NASDAQ Stock Exchange Capital Market

2.57USD
14 Dec 2018
Change (% chg)

$-0.08 (-3.02%)
Prev Close
$2.65
Open
$2.56
Day's High
$2.65
Day's Low
$2.56
Volume
1,918
Avg. Vol
32,706
52-wk High
$8.94
52-wk Low
$1.45

Latest Key Developments (Source: Significant Developments)

Xenetic Biosciences qtrly ‍loss per share $0.26​
Wednesday, 15 Nov 2017 07:24am EST 

Nov 15 (Reuters) - Xenetic Biosciences Inc -:Xenetic Biosciences Inc qtrly ‍loss per share $0.26​.Xenetic Biosciences Inc- ‍current cash position is about $8.0 million, sufficient to fund operations through Q2 of 2018​‍​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 08:05am EDT 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Xenetic Biosciences appoints Jeffrey Eisenberg as CEO
Tuesday, 31 Oct 2017 09:05am EDT 

Oct 31 (Reuters) - Xenetic Biosciences Inc -:Xenetic Biosciences appoints Jeffrey F. Eisenberg as chief executive officer.Xenetic Biosciences Inc- ‍Scott Maguire will continue to serve Xenetic during management transition​.  Full Article

Xenetic Biosciences reports Q2 loss per share $0.34
Tuesday, 15 Aug 2017 08:05am EDT 

Aug 15 (Reuters) - Xenetic Biosciences Inc :Xenetic biosciences reports 2017 second quarter financial results and provides business update.Qtrly loss per share $0.34.  Full Article

Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
Monday, 26 Jun 2017 08:35am EDT 

June 26 (Reuters) - Xenetic Biosciences Inc :Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer.Xenetic Biosciences Inc- Patient dosing expected in Q3 2017.  Full Article

Xenetic Biosciences reports Q1 loss per share $0.34
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - Xenetic Biosciences Inc -:Xenetic Biosciences reports 2017 first quarter financial results and provides business update.Xenetic Biosciences -on track to commence patient recruitment for lead product candidate xbio-101 for treatment of progestin resistant endometrial cancer.Xenetic Biosciences Inc qtrly loss per share $0.34.  Full Article

Xenetic Biosciences names new CFO
Tuesday, 4 Apr 2017 07:05am EDT 

Xenetic Biosciences Inc : Xenetic biosciences expands executive management team with appointment of James F. Parslow, MBA, CPA as chief financial officer .Xenetic Biosciences Inc says has appointed James F. Parslow as chief financial officer, effective April 3, 2017.  Full Article